Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Study reviews mechanistic data on new methods of allergy prevention and treatment

In a recent article published in Science Translational Medicine, researchers reviewed the cause and the underlying pathophysiology of allergic diseases.

23 Jan 2023

Understanding the mechanisms involved in heart disease and cancers

In a crucial step towards understanding the mechanisms involved in cardiovascular disease and certain cancers, a Canadian led research team has succeeded in a world first: they've found the molecular mechanism by which the protein PCSK9 degrades the receptor of low density lipoproteins, the richest cholesterol particles in the bloodstream.

19 Jan 2023

How do mutations in emergent SARS-CoV-2 Omicron variants affect viral function, human immunity, and recognition by therapeutic antibodies?

Researchers explored how mutations in emergent SARS-CoV-2 variants affect viral function, human immunity, and recognition by therapeutic antibodies.

19 Jan 2023

Researchers report that vectored expression of a high-affinity ACE2 microbody protein establishes a high degree of protection from SARS-CoV-2

Researchers evaluated the use of receptor decoys for SARS-CoV-2 based on soluble forms of ACE2 for immunological prophylaxis and management of COVID-19 through the use of AAV vectors.

16 Jan 2023

Bettersize Announces the Release of Nanoparticle Characterization Guidebook

Nanoparticles or nanomaterials are increasingly important due to their unique physical and chemical properties, such as particle size, zeta potential, and molecular weight.

From Bettersize Instruments Ltd. 16 Jan 2023

Study uncovers a new role for Slit2 signaling in stimulating Ewing sarcoma growth

A new research paper was published in Genes & Cancer on December 14, 2022, entitled, "Slit2 signaling stimulates Ewing sarcoma growth."

13 Jan 2023

Scientists explore efficacy of small molecule drugs against severe COVID-19 in vitro

Researchers evaluated the efficacy of small molecule drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro.

29 Dec 2022

Cell-based method can predict how breast cancer patients will respond to treatments

Researchers at Karolinska Institutet in Sweden have developed a method that should be able to predict whether a patient with breast cancer will benefit from a particular treatment or not.

27 Dec 2022

SARS-CoV-2 structural proteins trigger periodontal fibrosis

Researchers examined the pathological impacts of the structural components of SARS-CoV-2 on human periodontal cells and tissue to understand the association between coronavirus disease 2019 (COVID-19) and deteriorating oral health.

20 Dec 2022

Study identifies four new monoclonal antibodies with broad neutralizing potencies that target conserved SARS-CoV-2 epitopes

Researchers described four novel monoclonal antibodies with potent and broad neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including the current globally dominant Omicron BA.4/BA.5.

20 Dec 2022

Scientists identify a novel epitope at the SARS-CoV-2 spike furin cleavage site

Scientists identify an immunogenic epitope at the furin cleavage site of the SARS-CoV-2 spike protein.

15 Dec 2022

Study finds bebtelovimab therapy lacks efficacy in patients infected with SARS-CoV-2 Omicron subvariants

Researchers assessed the impact of bebtelovimab (BEB) monoclonal antibody in the treatment of high-risk SARS-CoV-2 Omicron variant-infected patients.

13 Dec 2022

Antibody discovery could explain why so many group A strep vaccines have failed

Researchers at Lund University in Sweden have discovered an antibody with the potential to protect against Strep A infection, as well as a rare form of antibody binding, that leads to an effective immune response against bacteria.

12 Dec 2022

Novel monoclonal antibody therapy shows promising results in patients with moderate to severe atopic dermatitis

Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab-;a novel, patient-tailored monoclonal antibody therapy-;showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet.

12 Dec 2022

Pre-existing SARS-CoV-2 antibodies may increase the breadth of mRNA vaccines, study suggests

Nearly three years into the pandemic, many of us now carry antibodies against the virus-;due to an infection or two, a few doses of mRNA vaccine, or a round of monoclonal-antibody treatment.

6 Dec 2022

Mucosal IgA fused nanobody as a non-invasive, cost-effective prophylaxis and therapeutic option against major SARS-CoV-2 variants

Researchers from the United States developed an affordable, non-invasive, inhalable prophylactic treatment consisting of immunoglobulin (Ig) A fused nanobodies against the SARS-CoV-2 Omicron variant.

2 Dec 2022

Prior infection and vaccination protects against severe outcomes from SARS-CoV-2 Omicron infection

Previous infection with SARS-CoV-2 and booster vaccination protect against ICU admission and mortality following infection with the Omicron variant.

1 Dec 2022

The antibody resistance profile and viral receptor binding affinity of SARS-CoV-2 Omicron BQ.1, BQ.1.1, XBB, and XBB.1 subvariants

Researchers investigated the neutralizing antibody titers against the newly emergent BQ.1, BQ.1.1, XBB, and XBB.1 SARS-CoV-2 Omicron subvariants using sera from individuals with primary and booster COVID-19 vaccinations and previous SARS-CoV-2 infections.

30 Nov 2022

Researchers use a comparative study to model RSV prevention in children

Using computational modeling, a new paper compares the benefit of maternal vaccines versus the administration of respiratory syncytial virus (RSV)-specific monoclonal antibody (mAb) therapy against RSV.

28 Nov 2022

Sino Biological announces construction of its new US-based center for bioprocessing

Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, which provides biological research reagents and related technical contract research services, is pleased to announce the formal signing of a lease with Hines and initiation of construction on its new Center for Bioprocessing at its Levit Green facility in Houston, Texas USA.

From Sino Biological Inc. 24 Nov 2022